Chris Martin, a veteran pharmaceutical executive, has been named chief executive officer of ADC Therapeutics Sarl, a developer of antibody-drug conjugates targeting cancer. Dr Martin played a leading role in the creation of ADC Therapeutics in 2012 and has served on its board of directors since that time.
He is also a co-founder of Spirogen Ltd, and was that company’s CEO leading up to its sale to MedImmune/AstraZeneca Plc in 2013. Following the sale, Dr Martin continued as the Spirogen CEO and was a member of AstraZeneca’s senior leaders’ group. He remains a consultant to MedImmune.
ADC Therapeutics is co-located in Lausanne, Switzerland and London, UK.
ADC Therapeutics announced the appointment on 22 June 2015.
Copyright 2015 Evernow Publishing Ltd